Translate Bio

Translate Bio was a clinical-stage biotechnology company focused on the development of messenger RNA (mRNA) therapeutics. Founded in 2011, the company pioneered a platform for designing and delivering mRNA to produce proteins within the human body to treat or prevent a wide range of diseases. Its work gained significant prominence during the COVID-19 pandemic, leading to its acquisition by the global pharmaceutical giant Sanofi in 2021 to accelerate the development of mRNA-based vaccines and medicines.

History

The company was originally founded in 2011 as RaNA Therapeutics by Ron Renaud and Michael Heartlein, initially focusing on targeting long non-coding RNA. In 2016, the company shifted its strategic direction entirely to mRNA technology and was rebranded as Translate Bio. This pivot was influenced by emerging research, including foundational work by pioneers like Katalin Karikó and Drew Weissman, which demonstrated the therapeutic potential of modified mRNA. Headquartered in Lexington, Massachusetts, within the prominent Boston biotechnology cluster, the company grew its operations and went public in 2018, listing on the NASDAQ under the ticker symbol TBIO. Its early research attracted attention from major pharmaceutical firms, setting the stage for significant future collaborations.

Technology and platform

Translate Bio's core technology centered on its MRT (mRNA Therapeutic) platform, which comprised advanced mRNA design, synthesis, and delivery systems. The platform utilized nucleotide chemistry, including modifications similar to those pioneered by Katalin Karikó, to enhance mRNA stability and reduce unwanted immune response. A critical component was its proprietary lipid nanoparticle (LNP) delivery technology, designed to encapsulate and protect mRNA molecules and facilitate their efficient uptake into target cells, such as in the lungs or liver. This delivery system was engineered to be modular, allowing it to be applied across various therapeutic areas, from infectious diseases to rare genetic disorders caused by protein deficiencies.

Clinical development and partnerships

The company's most advanced program was MRT5005, an inhaled mRNA therapy designed to treat cystic fibrosis by delivering mRNA encoding the functional CFTR protein directly to lung epithelial cells. This program entered Phase 1/2 clinical trials and represented a novel approach for the disease. Concurrently, Translate Bio established a major research and development collaboration with Sanofi Pasteur, the vaccines division of Sanofi, in 2018 to develop mRNA vaccines for infectious diseases. This partnership was expanded in 2020 to include broader infectious disease targets. The global urgency of the COVID-19 pandemic accelerated these efforts, with the collaboration rapidly advancing a COVID-19 vaccine candidate into clinical trials, though it did not reach the market.

Acquisition by Sanofi

In August 2021, Sanofi announced it would acquire Translate Bio in an all-cash transaction valued at approximately $3.2 billion. This acquisition was a strategic move by Sanofi to build a dedicated mRNA research and development capability following the demonstrated success of mRNA platforms during the pandemic. The integration led to the formation of an mRNA Center of Excellence within Sanofi, leveraging Translate Bio's platform and scientific team. The acquisition marked a significant consolidation in the biotechnology industry, highlighting the strategic value placed on next-generation mRNA technology beyond COVID-19, for applications in oncology, immunology, and rare diseases.

See also

* Moderna * BioNTech * CureVac * mRNA vaccine * Lipid nanoparticle * Biotechnology industry

Category:Biotechnology companies of the United States Category:Companies based in Massachusetts Category:Sanofi